Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazucorilant DDI with Itraconazole in Healthy Adults
NCT06495944Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dazucorilant in amyotrophic lateral sclerosis (ALS), sponsored by Corcept Therapeutics. Primary endpoints: Maximum observed plasma concentration of dazucorilant, Area under the concentration-time curve from time 0 to the last measurable concentration of plasma dazucorilant and 1 more. Started May 2024; status: completed.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06495944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495944.